online

The results of the Symplicity HTN-3 are finally out!

Simultaneously to the presentation of Deepak L. Bhatt in the Late-Breaking Clinical Trials session, ACC meeting 2014 in Washington D.C., the results are now published online in The New England Journal of Medicine.

The results of the Symplicity HTN-3 are finally out!

Simultaneously to the presentation of Deepak L. Bhatt (Brigham and Women's Hospital, Boston, MA) in the Late-Breaking Clinical Trials session, 63rd Scientific Sessions of the American College of Cardiology (ACC) 2014 in Washington D.C., the results are now published online in The New England Journal of Medicine. 

An interview with Ajay Kirtane

Ajay Kirtane (United States) answers the following questions:

- Can you tell us more about the treatment of difficult to control hypertension in the US and about the prevalence?...

Ajay Kirtane on Treatment of Difficult to Control Hypertension in the US

Ajay Kirtane (United States) answers the following questions:

- Can you tell us more about the treatment of difficult to control hypertension in the US and about the prevalence?
- Who refers you patients for interventional treatment of resistant hypertension?
- Are all patients screened for secondary causes?
- What is the status of device availability in the US?
- What are your thoughts about the Symplicity HTN-3 trial and how did the press release influence your work?

An interview with Riaz Dawood

Riaz Dawood (South Africa) answers the following questions: - Please tell us about the prevalence of hypertension and especially resistant hypertension in South Africa...

Riaz Dawood - About resistant hypertension in South Africa

Riaz Dawood (South Africa) answers the following questions:

- Please tell us about the prevalence of hypertension and especially resistant hypertension in South Africa
- Who refers the resistant hypertensive patients to you?
- What experience do you have with device-based treatments in South Africa?
- What did you enjoy at the RHC 2014 in Berlin?
- How did the update on the Symplicity HTN-3 trial affect your work?

 

Roland Schmieder - On the Symplicity HTN-3 press release and hypertension treatments

Roland Schmieder (Germany) answers the following questions:

- Please share with us your thoughts on the Symplicity HTN-3 press release
- How has this new information impacted your clinical practice as related to renal denervation?
- What is the vision of ESH on this matter?
- What are the most significant advancements in hypertension treatments in the past 5 years?

 

To leave a comment, please create your free account here !

Markus Schlaich discussing the "fil rouge" patients presented during RHC 2014

Markus Schlaich (Australia) answers the following questions:

- Can you tell us more about the RHC "fil rouge" patients presented in Berlin, and the objectives of using these patients?

- Please tell us more about your preferred therapy for the elderly patient, the metabolic patient and the young adrenergic patient

- What was your favorite session at RHC 2014 and why?

 

To leave a comment, please create your free account here !

Pages